This content is from: European Union

In depth: Why HGS ruling will benefit biotech investment

Yesterday’s Supreme Court decision in HGS v Eli Lilly gives applicants more certainty by bringing UK law on industrial applicability into line with that applied in the EPO

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Related

Instant access to all of our content. Membership Options | 30 Day Trial